| Dr Mark D Denney, OD | |
|
1340 S Ammon Rd, Ammon, ID 83406-5810 | |
| (208) 523-3141 | |
| (208) 525-2661 |
| Full Name | Dr Mark D Denney |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 25 Years |
| Location | 1340 S Ammon Rd, Ammon, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962569681 | NPI | - | NPPES |
| 000010026621 | Other | ID | BLUE SHIELD |
| 805561900 | Medicaid | ID | |
| V3918 | Other | ID | BLUE CROSS |
| 167539 | Other | ID | COLE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | ODP1012 (Idaho) | Primary |
| Provider Name | Dr Mark D Denney Od Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780890541 PECOS PAC ID: 2860590494 Enrollment ID: O20070606000081 |
News Archive
In an attempt to contain the spread of the disease, many countries worldwide, including Malaysia and other Southeast Asian (SEA) countries, have enforced lockdowns of varying degrees, which has inadvertently caused some positive changes to the environment.
"Two studies of malnourished children offer the first major new scientific findings in a decade about the causes and treatment of severe malnutrition, which affects more than 20 million children around the world and contributes to the deaths of more than a million a year," the New York Times reports.
A new study shows that a high percentage of military personnel with sleep disturbances met criteria for nightmare disorder, but few of them reported nightmares as a reason for sleep evaluation. Those with nightmare disorder had an increased risk of other sleep and mental health disorders.
Faster and more widely available internet access has improved our lives in many ways but healthcare is lagging behind, according to researchers writing in the International Journal of Medical Engineering and Informatics.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark D Denney, OD 1340 S Ammon Rd, Ammon, ID 83406-5810 Ph: (208) 523-3141 | Dr Mark D Denney, OD 1340 S Ammon Rd, Ammon, ID 83406-5810 Ph: (208) 523-3141 |
News Archive
In an attempt to contain the spread of the disease, many countries worldwide, including Malaysia and other Southeast Asian (SEA) countries, have enforced lockdowns of varying degrees, which has inadvertently caused some positive changes to the environment.
"Two studies of malnourished children offer the first major new scientific findings in a decade about the causes and treatment of severe malnutrition, which affects more than 20 million children around the world and contributes to the deaths of more than a million a year," the New York Times reports.
A new study shows that a high percentage of military personnel with sleep disturbances met criteria for nightmare disorder, but few of them reported nightmares as a reason for sleep evaluation. Those with nightmare disorder had an increased risk of other sleep and mental health disorders.
Faster and more widely available internet access has improved our lives in many ways but healthcare is lagging behind, according to researchers writing in the International Journal of Medical Engineering and Informatics.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 6 days ago
Aspen Ridge Eye Care, Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 3456 E 17th St, Suite 150, Ammon, ID 83406 Phone: 208-528-6900 Fax: 208-528-6904 | |
Dr. Daniel Glenn Nielson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1536 Midway Dr, Ammon, ID 83406 Phone: 208-227-8822 | |
Dr. Joshua G Davis, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1201 S 25th E, Ammon, ID 83406 Phone: 208-524-8978 | |
Carl L. Giauque, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1201 S 25th E, Ammon, ID 83406 Phone: 208-524-8978 Fax: 208-524-8980 | |
National Vision Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3421 South 25th Street East, Ammon, ID 83406 Phone: 986-497-6251 | |
Frederick G. Downard, O.d., P.a. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1990 Sabin Dr, Ammon, ID 83406 Phone: 208-522-6933 | |
Dr. Aaron Taylor, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3421 South 25th Street East, Ammon, ID 83406 Phone: 986-497-6251 |